Filter posts

Small Companies, Big Returns

The broader biotech indices are up more than 30 percent this year and have reached …

Big Ventures

It is rare to see triple digit millions in private financing rounds, but it does …

The Good, the Bad, and the Ugly for Biotech IPOs

The troubles in the biotech IPO market are complicated to explain to industry outsiders. They …

Choose Your Own Adventure – The Private Biotech Crossroads

It is a known fact within the private company biopharma universe that the days of …

Kinase Drug Development - Making Progress

The kinase inhibition field has had plenty of ups and downs and over the last …

BIO Investor Forum: The New Kids on the Biotech Block

Where should biotech start-ups look for funding in the venture capital desert that is becoming …

How does the NBI perform in the last quarter of the year?

Does the NASDAQ Biotech Index (NBI) outperform the broader market in the last three months …

Is the early-stage IPO making a comeback?

Yesterday was the NASDAQ debut for preclinical-stage biotech Regulus (RGLS). The microRNA platform company is …

Indices, IPOs, Approvals - YTD Update Aug 14th, 2012

We are now more than eight months into the year and biotech indices have maintained their outperformance, squeezed …

Indices, IPOs, and New Drug Approvals – Update July 6th 2012

1. Stock Performance. The Nasdaq Biotech Index (NBI) continued on its path of outperforming the …